Decernotinib, also known as VX-509 or VRT-831509 or adelatinib, is an oral, selective Janus kinase 3 (JAK3) inhibitor being developed by Vertex. VX-509 may represent a new approach to treating an underlying disease mechanism that triggers inflammation in a number of debilitating diseases, including RA. In immune-mediated diseases, JAK3 is an essential component of the immune signaling cascade. This cascade ultimately contributes to abnormal immune response that results in chronic inflammation and, in the case of RA, irreversible damage to cartilage and bones.
JAK Inhibitors Related Products:
Ruxolitinib; Ruxolitinib phosphate; Tofacitinib; AZD1480; Momelotinib; Gandotinib; AZ960; Pacritinib; XL019; Upadacitinib; Filgotinib; GLPG0634 analogue; FLLL32; AG-490 (Tyrphostin B42); NSC-42834; Itacitinib; Go6976; Baricitinib; Oclacitinib; Oclacitinib maleate; WP1066